Clinical Trial

A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2025 (before its estimated August 3, 2026 completion). Its status may not reflect the trial's current state.
Summary
This open-label, multicenter, rollover study will provide continued treatment for participants deriving benefit from different therapies received in studies sponsored by Daiichi Sankyo, Inc. (DS) or DS/Astra Zeneca (AZ)-sponsored study (eg. DS8201-A-J101, DS8201-A-U201, DS8201-A-U204, DS8201-A-U207, DS8201-A-U303).
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-12-08; most recent amendment 2025-10-10.
Status change: Not Yet Recruiting → Recruiting 2024-05-01
Trial Details
NCT Number NCT06174987
Lead Sponsor Daiichi Sankyo
Collaborators: AstraZeneca
Conditions Advanced Cancer, Metastatic Cancer
Enrollment 50 participants
Start Date 2024-01-05
Primary Completion 2026-08-03 (estimated)
Study Completion 2028-01-17 (estimated)
Updated on ClinicalTrials.gov 2025-10-15